Table 1.
Baseline patient characteristics
| Characteristic | SZC (n = 97) | Placebo (n = 99) |
|---|---|---|
| Age, years, mean (SD) | 55.7 (13.8) | 60.4 (13.2) |
| Sex, male, n (%) | 57 (58.8) | 58 (58.6) |
| Race, n (%) | ||
| White | 50 (51.5) | 52 (52.5) |
| Black or African American | 11 (11.3) | 8 (8.1) |
| Asian | 33 (34.0) | 33 (33.3) |
| American Indian or Alaska Native | 1 (1.0) | 2 (2.0) |
| Other | 2 (2.1) | 4 (4.0) |
| Height, cm, mean (SD) | 166.4 (9.9) | 165.1 (9.2) |
| Weight, kg, mean (SD) | 72.0 (22.0) | 70.0 (15.9) |
| BMI, kg/m2, mean (SD) | 26.9 (7.1) | 26.7 (5.4) |
| Pre-dialysis serum potassium concentration, mmol/L, mean (SD)a | 5.8 (0.6) | 5.9 (0.6) |
| Dialysis history | ||
| Vintage, years, mean (SD) | 8.0 (6.1) | 7.8 (7.6) |
| Access type, n (%) | ||
| Arteriovenous fistula | 84 (87.5) | 90 (90.9) |
| Arteriovenous graft | 7 (7.3) | 3 (3.0) |
| Tunneled central venous catheter | 4 (4.2) | 6 (6.1) |
| Other | 1 (1.0) | 0 (0.0) |
| Total | 96 (100.0) | 99 (100.0) |
| Dialysis adequacy | ||
| spKt/V, mean (SD) | 1.7 (0.3) | 1.7 (0.4) |
| Urea removal rate, %, mean (SD) | 72.9 (6.7) | 74.6 (5.6) |
| Dialysate flow, ml/min, mean (SD) | 512.0 (162.8) | 538.5 (136.0) |
| Dialysis potassium concentration, mmol/L | ||
| Mean (SD) | 2.26 (0.49) | 2.26 (0.47) |
| Minimum, maximum | 1.0 to 3.0 | 1.0 to 3.0 |
| Blood flow, ml/min, mean (SD) | 322.0 (110.7) | 318.5 (96.3) |
Republished with the permission of American Society of Nephrology, from A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia, Fishbane S et al. JASN. Sep 2019;30(9):1723-1733; permission conveyed through Copyright Clearance Center, Inc.
BMI body mass index, SD standard deviation, spKt/V single-pool Kt/V, SZC sodium zirconium cyclosilicate
aVisit 4 (Day 1)